Impact of Rosuvastatin Treatment on HDL-Induced PKC-βII and eNOS Phosphorylation in Endothelial Cells and Its Relation to Flow-Mediated Dilatation in Patients with Chronic Heart Failure

Table 2

Flow-mediated dilatation and blood lipids.

	Baseline	12 weeks	16 weeks
FMD [%]
Rosuvastatin	7.56 ± 1.61
Placebo	4.73 ± 0.88	4.74 ± 1.01	5.14 ± 0.68
LDL [mmol/L]
Rosuvastatin	3.30 ± 0.17
Placebo	3.91 ± 0.27	3.12 ± 0.36	3.31 ± 0.45
HDL [mmol/L]
Rosuvastatin	1.17 ± 0.10	1.26 ± 0.08	1.16 ± 0.09
Placebo	1.21 ± 0.12	1.19 ± 0.10	1.28 ± 0.14

Repeated measures ANOVA for baseline versus 12 weeks.
Repeated measures ANOVA for 12 weeks versus 16 weeks.